Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
Terug naar discussie overzicht
Ik heb even de compounds in de glossary van het jaarverslag 2020 vergeleken met die van 2019: 5 nieuwe: Glpg4876: new Toledo Sik2/3 Glpg4716: oatd-01 Glpg4605: new Toledo sik2/3 GLPG4586: FIB656 Glpg4399: Toledo 3 verwijderd: Glpg4124: novel MOA for fibrosis Glpg4259: backup for inflammation Glpg4471: backup for inflammation
Op de laatste pagina van het jaarverslag kan je zien dat Sandra Cauwenberghs, ex-biotech-analiste van KBC Securities het IR-team van Galapagos heeft versterkt als “Director of Investor Relations”. Volgens haar LinkedIn heeft ze de overstap gemaakt in nov20. Sofie Van Gijsel heeft sinds jun20 de promotie gemaakt naar “Senior Director of Investor Relations“.
Is deze hier al gepasseerd? twitter.com/CrohnsColitisUK/status/13... Het lijkt wel een gesponsord artikel; al zie ik er niet meteen een referentie naar in het DailyMail artikel.
Ornito schreef op 29 maart 2021 21:02 :
Is deze hier al gepasseerd?
twitter.com/CrohnsColitisUK/status/13... Het lijkt wel een gesponsord artikel; al zie ik er niet meteen een referentie naar in het DailyMail artikel.
Ook Nederlandse versie:whatsnew2day.com/nieuwe-dageraad-in-d...
Lijkt toch verdácht veel op dat "spontane" tripje van "De Tijd" naar Moldavië.www.iex.nl/Leden/1766397/Ornito.aspx Brrr...
Wat is je (inhoudelijk) punt?
Wat is jóuw punt? Moeten jullie hier extra 'n account aanmaken om te melden dat de behandeling met Filgo in minstens één patiënt is aangeslagen? Steek je moeite liever in heldere communicatie en zorg ervoor dat 't spul bij de autoriteiten 't juiste stempeltje meekrijgt.
Fout. Gebruik de zoekfunctie op dit forum. Dan kan je zien dat dit niet mijn eerste bijdrage was. En nu graag opnieuw inhoudelijk.
AbbVie has pegged multibillion-dollar hopes on Rinvoq to fill the revenue gap when immunology superstar Humira loses U.S. market exclusivity. But that plan, dependent on multiple label expansions, has hit its second regulatory setback in weeks. by Angus Liu | Apr 5, 2021 10:45amThe FDA has pushed back a decision on an application for Rinvoq in moderate to severe atopic dermatitis by three months, as the agency—which has concerns about the safety of meds in the JAK inhibitor class—needs more time to review additional information the company submitted at its request, AbbVie said Friday. The verdict is now expected early in the third quarter. The news didn’t come as a surprise. It followed another three-month delay for Rinvoq’s filing in psoriatic arthritis, which the Illinois pharma unveiled mid-March. At the time, AbbVie disclosed that the FDA had requested additional information on the benefit-risk profile for the JAK inhibitor in eczema , too. In eczema, AbbVie has predicted peak sales of Rinvoq to hit around $2 billion in 2025. The internal estimate came from an investor update in December, when management dialed up its combined peak projection for Rinvoq and fellow immunology rising star Skyrizi to $15 billion after a series of clinical wins for the two meds. Rinvoq topped Sanofi and Regeneron eczema big shot Dupixent in a phase 3b head-to-head trial. The AbbVie drug helped more patients achieve 75% improvement on an eczema severity scale after 16 weeks, and it also hit several secondary endpoints evaluating its ability to clear skin and reduce itch. At the time, industry watchers said they expected Rinvoq to be used after Dupixent in practice because of the AbbVie drug’s relatively weaker safety profile, most notably an increased risk of infection. But the FDA’s concern is not about the infection, but about potential heart problems that have been haunting the entire JAK inhibitor drug class. The FDA’s requests for more data on Rinvoq in eczema and psoriatic arthritis are “essentially identical and are focused solely on the long-term safety data that Pfizer released for Xeljanz in late January,” Mizuho analyst Vamil Divan wrote in a note after talking to AbbVie when the first delay was announced. Xeljanz, also a JAK inhibitor, was linked to higher risk of cardiovascular events and cancers compared with traditional TNF inhibitors—such as Humira—in a post-marketing rheumatoid arthritis trial required by the FDA. The study was carried out in a group of high-risk patients. Before that, the FDA first noted problems with a high dose of Xeljanz in 2019 and immediately slapped a restriction on that use. The agency is now weighing whether to take further action against the Pfizer drug, given the final analysis showed risks for both doses tested. And as Divan views it, the agency might be looking at the Xeljanz issues as a potential class effect.Before the Xeljanz debacle, the agency had already rejected Gilead Sciences’ JAK inhibitor filgotinib in rheumatoid arthritis, though mainly on the drug’s sperm toxicity. Eli Lilly’s JAK drug Olumiant carries a black box warning covering serious infections, lymphoma and other malignances, and blood clots. Rinvoq, in its currently approved rheumatoid arthritis indication, also bears a boxed warning about those same safety problems mentioned on Olumiant's label—and that’s for a 15-mg once-daily dose. For eczema, AbbVie is seeking a green light for a 30-mg dose, and the drug’s recent clinical win in ulcerative colitis features a 45-mg version. The fact that AbbVie’s only pegging $2 billion in peak sales for Rinvoq in an eczema market worth more than $10 billion is evidence that AbbVie expects challenges advancing the higher 30-mg dose, SVB Leerink analyst Geoffrey Porges said in a note in December. In a separate report in December, Porges noted that results for 15-mg Rinvoq weren’t shared in the top-line eczema trial announcement despite the drug showing fairly robust efficacy in two earlier pivotal trials. “If the 15-mg dose failed to match Dupixent’s efficacy it will be a liability for AbbVie should the FDA impose their usual restrictions on higher doses of JAK inhibitors,” he said at the time.www.fiercepharma.com/marketing/abbvie...
Maar voor reuma is het wel Ok?
Galapagos Momentum/Summary of where we stand today and Key Takeaways 2021 What’s next for Gilead? It still has a right to opt-in if any new interesting drug emerges from Galapagos’s pipeline. Galapagos funds and leads all discovery and development autonomously until the end of Phase 2. After the completion of a qualifying Phase 2 study, Gilead will have the option to acquire a license to the compound outside Europe. If the option is exercised, Galapagos and Gilead will co-develop the compound and share costs equally. Gilead will maintain option rights to the programs through the 10-year term of the collaboration and for up to an additional three years thereafter for those programs that have entered clinical development prior to the end of the collaboration term. For all other programs resulting from the collaboration, Gilead will make a $150 million opt-in payment per program and will owe no subsequent milestones. Galapagos will receive tiered royalties ranging from 20-24% on net sales of all products licensed by Gilead in all countries outside Europe as part of the agreement. In August 2019, Gilead and Galapagos entered into a 10-year global transformative research and development collaboration, giving Gilead access to Galapagos’ innovative portfolio of compounds and drug discovery platform. As part of the transaction, Gilead made a $1.1B equity investment, increasing Gilead’s stake in Galapagos from approximately 12.3% to 22% of the issued and outstanding shares in Galapagos. In addition, Galapagos issued two warrants, allowing Gilead to further increase its ownership of Galapagos to up to 29.9% of the company’s issued and outstanding shares. Through the exercise of a first warrant, Gilead’s shareholding further increased to 25.1%. The most recent transparency notice received by Galapagos from Gilead indicates a 25.5% ownership position. The amendment announced the full lock-up is extended: Gilead is now committed to a full lock-up of 5 years, retaining all of its 16,707,477 shares (currently 25.5%) until 22 August 2024. Previously, there was a full lock-up of 2 years, followed by a 3-year period during which the company would have held a minimum of 20% of outstanding shares. The lock-up restrictions are subject to certain exceptions as provided in the share subscription agreement.Commenting on the amendment, Gilead CFO Andrew Dickinson said, “We remain strongly committed to our long-term collaboration. We continue to see significant value in Galapagos’ unique target discovery approach, and we support Galapagos, as the company works to deliver on this potential.” Jyseleca (Filgotinib) UPDATE. Gilead decided not to pursue FDA approval of filgotinib for RA. While both Gilead and Galapagos continue to believe in the clinical profile of the 200 mg dose, Gilead concluded that this dose was required to be competitive in RA in the U.S. and that the 200 mg dose is unlikely to achieve approval for RA in the U.S. without conducting substantial additional clinical studies. Both companies continue to pursue the inflammatory bowel disease (IBD) opportunity with filgotinib and the Phase 3 DIVERSITY program in Crohn’s disease (CD) continues to recruit patients. The filgotinib launch in Japan and Europe is currently underway for rheumatoid arthritis (RA), and an EMA decision on ulcerative colitis (UC) is expected in 2H21 (CHMP in 1H21). With the DIVERSITY study reading out in 1H22, there may be potential for a Crohn's disease (CD) filing in 2H22. Through a phased transition period, the majority of activities supporting and commercializing filgotinib in Europe are expected to be assumed by Galapagos by the end of 2021. Filgotinib is now on the market in Germany, Italy, and The Netherlands, with other European territories scheduled to follow in the course of 2021.www.ema.europa.eu/en/documents/produc... What about the US? In the US, Gilead has terminated development for filgotinib in all indications besides inflammatory bowel disease (IBD). The next step on this front is the MANTA safety study. MANTA is required for approval in UC, and following the Type A meeting, the FDA requested an increased 52-week follow-up from the 26-week primary endpoint for any patients who display >50% decrease in semen parameters and do not recover at 26 weeks. The data will remain blinded, except to a specific team responsible for reviewing the data and conducting discussions with regulators. While it is possible that the company will be able to file before the 52-week endpoint (no signals on hormone levels have been detected across trials, which should correlate with semen parameter), semen parameters can be highly variable, so filing will likely have to wait until the full data is available. Gilead will only move forward in the US market for IBD indications if they believe there is a best-in-class profile. Based on results from the FINCH trials, Gilead believes that a 200mg dose is required to be competitive in rheumatoid arthritis (RA) in the US. As such, it is not clear yet if a low dose would be compelling for the US market. Gilead expects to have additional discussions with the FDA following the MANTA and MANTA-RAy data readouts.
IPF Two more shots on goal in the IPF pipeline. Galapagos still has several opportunities over the longer term. In particular, GLPG1205 demonstrated positive Phase2 data and has become the lead asset in IPF. Galapagos now has two mid-stage assets in its IPF franchise - GLPG1205 , which will enter a Phase2b in 2021 and GLPG4716 , which is expected to enter a Phase2b in 4Q21/1Q22. As GLPG1205 and GLPG4716 have different MOAs analysts don't see an immediate readthrough. Top-line data from these two assets is expected in 2023-2024. For GLPG4716, we can assume US, EU and Japan launch in 2030/2031/2031 respectively. Analysts forecast peak risk unadjusted sales of ~ €1.3bn in 2035.What about acquisitions? Galapagos Management plans to fill the gap in the pipeline left by ziri with in-licensing or acquisitions of anti-fibrotic/inflammatory assets, with a focus on novel targets and MoAs. With the purchase of the European sales rights for a drug from an American company, Galapagos could close the gap to the start of sales of new drugs from the Toledo program. They are also considering an acquisition of a biotech company or the licensing of a drug that is in the third research phase and can therefore be marketed within a few years. They mainly look at drugs that are closest to their research programs. They will only make really large acquisitions, worth say € 1 billion, together with their American partner Gilead.License deals with: Fibrocor Therapeutics (Targets; 1st target moved to PCC), OncoArendi (Phase 2 ready chitinase program), Scipher Medicine (Targets) and Ryvu Therapeutic (Lead optimization) strengthen the internal pipeline.Where does Galapagos go from here? Within their broader inflammation portfolio, they expect to report topline results from several trials, including a Phase 1b trial with TYK2 inhibitor GLPG3667 in psoriasis, a Phase 1b trial with JAK1 inhibitor GLPG0555 via intra-articular injection in OA. GLPG555 economics: partnership with GSK was terminated, so now fully owned by GLPG. Three Proof of Concept studies with lead Toledo candidate SIK2/3 inhibitor GLPG3970 in psoriasis, UC, and RA. The Toledo program is early stage but promising, and data readouts are expected over 2021. Galapagos is running a number of proof-of-concept studies for the Toledo program, notably for GLPG3970 in psoriasis, RA, and ulcerative colitis (CALOSOMA, LADYBUG, and SEA TURTLE, respectively).See Key newsflow TOLEDO below: www.iex.nl/Forum/Upload/2021/13283541... It is important to remember that Gilead paid Galapagos $3.95B (+ a $1.1B equity investment) to maintain the option to in-license the ex-European commercial rights to each of the Toledo molecules following completion of Phase 2 Trials. Gilead will be able to opt in to each molecule and split development costs going forward in Phase 3. In addition, filgotinib is also not out of the picture, but the European markets and irritable bowel syndrome in the US are likely to drive more modest sales compared to other inflammatory drugs. Jyseleca peak sales guidance of €0.5bn, which assumes 8-12% market share. EU5 inflammation market is estimated at €5.7bn (RA: €3.2bn, UC: €0.8bn, CD: €1.7bn). Patent exclusivity until 2035. Jyseleca in RA is differentiated by its fast onset of action, ability to use as monotherapy, lasting activity, and safety profile.The company still has ~ $6B in cash and has the time to develop its earlier stage pipeline, but most analysts need to see more data emerge from these programs and gain clarity if/when value drivers emerge . As such, most analysts are stepping to the sidelines, downgrading the shares to Hold, from Buy and removing their price targets. YE'21 cash position estimate is ~ € 73 a share. The next potentially meaningful catalysts are the results from phase 2a with GLPG3970 (SIK2/3 inhibitor, also known as TOLEDO) in psoriasis, RA, and Ulcerative Colitis expected in the summer/mid'21.These potential catalysts could boost the share price, pharma alliances or deals could provide further upside.
Barbet01: "Afgelopen weekend stuurde ik een heel opportunistisch mailtje naar IR van Gilead. Reden waarom ik mailde is enerzijds mijn ongeduld tot duidelijkheid m.b.t US en anderzijds de signalen die Gilead tijdens conference calls zelf gaf. Hierbij de vragen en hun antwoorden." Investor questions and the reply from Gilead Investor Relations. Is Gilead still interested in gaining US market approval for Filgotinib in IBD indications? Yes, we are still exploring filgotinib in IBD indications. Of note, we will only move forward in the US market for IBD indications if we believe there is a best-in-class profile.Manta outcome: is Gilead able to file for Ulcerative Colitis soon? Pending additional MANTA and MANTA-Ray data readouts, we look forward to discussions with the FDA to help determine the best path in the US.Isn’t there an option for Gilead to sell US rights for RA low dose to another firm (like Pfizer or so)? Based on results from the FINCH trials, we believe that a 200mg dose is required to be competitive in rheumatoid arthritis (RA) in the US. As such, it is not clear yet if a low dose would be compelling for the US market.“Best in class profile”; could that also be best in class safety profile? Given FDAs current view in JAK class? To determine whether a therapy is best-in-class, we take into consideration both safety and efficacy as well as an assessment of how that would compare to other treatments for that specific indication. While there has been some recent safety concern emerging from a JAK study, FDA hasn’t issued any recent communication on the class and we’ll continue to monitor for regulatory updates here.So there will be future discussions with FDA regarding the 52week follow up demand? Yes, we expect to have additional discussions with the FDA following the MANTA and MANTA-RAy data readouts.What do you mean with “not clear yet”? Could Gilead still proceed with the low dose in RA if other indications with the high dose would be approved? Or what is not clear yet? That other firms would be interested? For RA in the US, we have decided not to pursue a filing and Galapagos will assume responsibility for this program. As such, we would refer you to the Galapagos team on their go-forward plans for any dose in the US for the treatment of RA. However, we would add that given the level of competition in the US, the 200mg high-dose is required to be competitive in RA. If the other doses are successful in other indications, there would not be a direct read-through to RA given the differences in the disease and market.Was thinking only EU rights were for GLPG? Correct, we returned rights to Europe to Galapagos and in the US, Galapagos assumes responsibility for ongoing clinical trials evaluating filgotinib in RA.So they can go to the market in US for RA by themselves? Gilead retains commercial rights in the US, however, Gilead has concluded that it does not see a viable path forward for RA in the US. Gilead believes a 200mg dose is required to be competitive in the US RA market, but given the FDA’s feedback, it is unlikely that a 200mg dose for RA will receive approval in the US without conducting substantial additional clinical studies. As noted in Q1, Galapagos assumes responsibility for ongoing clinical trials evaluating filgotinib in RA.Or they may find a partner other than Gilead to do so for them with only the low dose? And what if Gilead is going to US market in IBD indications? I heard that it would be a problem (it was said in an interview) if two different firms would sell the same product? Gilead believes that to be competitive in RA, we would need to have the 200 mg dose. As we do not see a path forward, we will not pursue FDA approval of filgotinib in RA. For IBD, Gilead and Galapagos continue to investigate the potential role of filgotinib in UC and Crohn’s disease, and will assess its clinical and commercial viability in the US pending data. As a reminder, last year, Galapagos filed for approval in Europe for UC.When will investors know more about Manta and outcome with FDA? We anticipate additional MANTA and MANTA-RAy data in Q221 , and will engage in discussions with FDA once the full readout is available.investors.gilead.com/investor-resourc...
Hoezo niet de 100 mg op de markt brengen en mensen kunnen dan zelf alsnog extra slikken? Of is dat onethisch.
Galapagos treedt toe tot de Business Club Rijksmuseum Boerhaave. Op maandag 12 april jl. trad Galapagos toe tot de Business Club Rijksmuseum Boerhaave. CEO en oprichter van Galapagos, Onno van de Stolpe, kwam persoonlijk naar het museum voor de start van het lidmaatschap. Hij liet zich fotograferen voor de wand met röntgenfoto's in één van de museumzalen. "Deze ontdekking zorgde voor een revolutie in de medische technologie. Het is inspirerend dat Wilhelm Röntgen maar liefst 125 jaar geleden een ontdekking deed die wij vandaag de dag nog steeds op allerlei manieren gebruiken in de geneeskunde." Dit is een van de vele inspirerende verhalen in het museum over hoe de ontdekkingen van wetenschappers van onschatbare waarde zijn voor ons eigen leven.rijksmuseumboerhaave.nl/documents/397...
www.bloomberg.com/press-releases/2021... Global Kinase Inhibitors in Autoimmune Diseases Market to Continue on Growth Trajectory with 19.17% CAGR During the Study Period (2018-2030), Asserts DelveInsight Pfizer, Eli Lilly, AbbVie, Gilead Sciences, Astellas Pharma, Japan Tobacco and Torii Pharmaceutical, Reistone Biopharma, Bristol Myers Squibb, Galapagos NV, Aclaris Therapeutics, Taiho Pharma, Oncostellae, Novartis Pharmaceuticals, Aclaris Therapeutics, Theravance Biopharma and Janssen (Johnson & Johnson), Kadmon Pharmaceuticals, Incyte Corporation, and others are the major players working in Global Kinase Inhibitor in Autoimmune Diseases Market regimen. Besides the JAK inhibitors, compounds that target other kinase inhibitors such as SYK , SRC- family kinases, TYK2 or BTK inhibitors are expected to emerge as new therapy for autoimmune diseases hopes for TYK2 inhibition. Global Kinase Inhibitor in Autoimmune Diseases Emerging Therapies Along with Key Players * Ritlecitinib: Pfizer * PF-06650833/Tofacitinib: Pfizer * SHR0302: Reistone Biopharma * Abrocitinib: Pfizer * Ruxolitinib: Incyte Corporation * Branebrutinib: Bristol Myers Squibb * GLPG3970: Galapagos NV * ATI-450: Aclaris Therapeutics * TAS5315: Taiho Pharma * OST-122: Oncostellae * Remibrutinib: Novartis Pharmaceuticals * ATI-1777: Aclaris Therapeutics * Izencitinib: Theravance Biopharma and Janssen (Johnson & Johnson) * PF-06826647: Pfizer * Deucravacitinib (BMS-986165): BMS * PF-06700841 (Brepocitinib): Pfizer * Belumosudil: Kadmon Pharmaceuticals * Elsubrutinib: AbbVie
www.abivax.com/events/ Abivax heeft een webinar geplaatst dat draait om hun medicijn tegen IBD, waarbij ook andere medicijnen, zoals JAKi, voorbij komen. Ik wist niet zeker waar ik deze moest plaatsen, maar het is in ieder geval wel zware kost.
PERSBERICHT: Gilead Sciences dient goedkeuringsaanvraag in Japan in voor filgotinib voor de behandeling van colitis ulcerosa bij patiënten met onvoldoende respons op conventionele behandelingen Aanvraag is gebaseerd op fase 2b/3 SELECTION-studieresultaten bij patiënten met matige tot ernstige actieve colitis ulcerosa Mechelen, België; 23 april 2021; 06.01 CET; -- Galapagos NV (Euronext & Nasdaq: GLPG) meldt vandaag dat haar samenwerkingspartner Gilead Sciences K.K. (hierna genoemd "Gilead") en Eisai Co., Ltd. ("Eisai") vandaag bekend hebben gemaakt dat Gilead een aanvraag heeft ingediend bij het Japanse Pharmaceuticals and Medical Devices Agency (PMDA) voor de goedkeuring van filgotinib voor een bijkomende indicatie voor de behandeling van patiënten met matige tot ernstige actieve colitis ulcerosa (CU). Filgotinib is een nieuwe orale Janus kinase (JAK)-remmer die in september 2020 in Japan werd goedgekeurd voor de behandeling van reumatoïde artritis. Deze meest recente indiening bij de regelgevende instanties is gebaseerd op resultaten uit de gerandomiseerde, dubbelblinde, placebogecontroleerde fase 2b/3 SELECTION-studie. Deze studie werd opgezet om de werkzaamheid en veiligheid van filgotinib te beoordelen bij de aanzet en behoud van remissie bij patiënten met matige tot ernstige actieve CU die onvoldoende respons toonden, respons verloren, of intolerant waren voor conventionele behandelingen of biologische middelen. Deze studie toonde aan dat, vergeleken met placebo, een significant hoger percentage patiënten behandeld met eenmaal daags filgotinib 200mg klinische remissie bereikte in week 10, en in remissie bleven tot en met week 58; er werden geen nieuwe veiligheidsrisico's vastgesteld. CU is een chronische ziekte die gekenmerkt wordt door ontsteking van de slijmvlieswand van de dikke darm en endeldarm. De laatste jaren komt CU steeds vaker voor. De ziekte heeft een aanzienlijke impact op de levenskwaliteit van meer dan 2 miljoen mensen wereldwijd. Zelfs bij patiënten die worden behandeld, komen ontlastingsdrang en incontinentie, terugkerende bloederige diarree, frequente stoelgang, buikpijn, slapeloosheid en vermoeidheid nog veel voor. CU kreeg de status van intractable disease(1) toegekend door het Japanse Ministerie van Volksgezondheid, Werk en Welzijn. Volgens een nationaal onderzoek bedroeg het geschatte aantal patiënten met CU in 2014 in Japan 219.685, met een gerapporteerde jaarlijkse prevalentie van 100.000 vs. 172,9 (192,3 voor mannen; 154,5 voor vrouwen).(2) Over filgotinib Filgotinib is goedgekeurd en wordt op de markt gebracht als Jyseleca (200mg en 100mg tabletten) in Europa, het VK en Japan voor de behandeling van volwassenen met matige tot ernstige actieve RA die eerder onvoldoende hebben gereageerd op of intolerant zijn voor één of meerdere ziekte-modificerende anti-reumatische geneesmiddelen (disease modifying anti-rheumatic drugs; DMARDs). Filgotinib kan worden gebruikt als monotherapie of in combinatie met methotrexaat (MTX). De Europese samenvatting van de productkenmerken (Full European Summary of Product Characteristics) van filgotinib, die contra-indicaties en speciale waarschuwingen en voorzorgsmaatregelen bevat, is beschikbaar op www.ema.europa.eu. Het beoordelingsformulier van het Japanse Ministerie voor Gezondheid, Werk en Welzijn (Japanese Ministry of Health, Labour and Welfare, MHLW) is beschikbaar opwww.info.pmda.go.jp. De samenvatting van productkenmerken (Great Britain Summary of Product Characteristics) van filgotinib voor het Verenigd Koninkrijk is beschikbaar op www.medicines.org.uk/emc. Aanvragen zijn ingediend bij de Europese Commissie, het MHRA en het PMDA voor een aanvullende indicatie voor de behandeling van volwassenen met matig tot ernstig actieve CU die een onvoldoende respons hebben gehad op, een niet langer reageren op, of intolerant waren voor een conventionele therapie of een biologisch middel. Deze aanvragen worden momenteel geëvalueerd. Filgotinib is in geen enkel ander rechtsgebied goedgekeurd. Over de samenwerking rond filgotinib Gilead en Galapagos NV zijn samenwerkingspartners voor de wereldwijde ontwikkeling en commercialisering van filgotinib. Galapagos zal verantwoordelijk zijn voor de commercialisering van filgotinib in Europa (transitie verwacht om eind 2021 afgerond te zijn), terwijl Gilead verantwoordelijk is voor filgotinib buiten Europa, ook in Japan, waar filgotinib samen met Eisai op de markt wordt gebracht. Filgotinib is in Europa ingediend voor CU en er loopt een wereldwijd fase 3-programma voor de ziekte van Crohn. Meer informatie over de klinische studies is te vinden opwww.globenewswire.com/Tracker?data=Wb... Over Galapagos Galapagos NV ontdekt en ontwikkelt geneesmiddelen met nieuwe werkingsmechanismen. Sommige geneesmiddelen leverden al veelbelovende resultaten op bij patiënten, en bevinden zich momenteel in een vergevorderd onderzoeksstadium in verschillende ziektes. Onze pijplijn bestaat uit onderzoeksprogramma's tot en met fase 3-studies op het gebied van ontstekingsziekten, fibrose en andere indicaties. Onze ambitie is om uit te groeien tot een toonaangevend internationaal biofarmaceutisch bedrijf, gericht op het ontdekken, de ontwikkeling en het op de markt brengen van innovatieve geneesmiddelen. Meer informatie opwww.globenewswire.com/Tracker?data=Wb... Contactpersonen Investeerders: Elizabeth Goodwin VP Investor Relations +1 781 460 1784 Sofie Van Gijsel Senior Director Investor Relations +32 485 19 14 15 www.globenewswire.com/Tracker?data=sz... Media: Carmen Vroonen Global Head of Communications & Public Affairs +32 473 824 874 Anna Gibbins Senior Director Therapeutic Areas Communications +44 7717 801900 www.globenewswire.com/Tracker?data=DC...
jobs.sciencecareers.org/job/543913/as... Gilead zoekt een Associate director global value and access heor inflammation pipeline. Heor = Health economics and outcomes research (HEOR) is a discipline that is used to complement traditional clinical development information (ie, efficacy, safety, quality) to guide decision makers regarding patient access to specific drugs and services. Key Responsibilities zijn best boeiend. Wil allemaal niets zeggen natuurlijk... maar feit dat ze hier (nog steeds) voor aanwerven, want hun eigen inflammatory pipe is vrij beperkt en early stage. Zie ze toch graag verschijnen, zulke vacatures.
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
AIRBUS
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
CVC Capital Partners
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia Oyj
Nokia OYJ
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)